Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROMANA-3 extension study of anamorelin in NSCLC-associated cachexia
NL-OMON38190Phase 3Active, not recruiting
- Sponsor
- Helsinn Therapeutics (U.S.), Inc
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cancer anorexia-cachexia syndrome (CACS) and non-small cell lung cancer (NSCLC) comparing Anamorelin continuation with Placebo continuation (2 arms). Primary endpoint: Safety and tolerability. Started Nov 2011; status: active, not recruiting.
02
Drugs
anamorelin
03
Conditions
cancer anorexia-cachexia syndrome (CACS)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON38190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38190.